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A B S T R A C T
Background
Bronchiectasis is a chronic inflammatory disease characterised by a recurrent cycle of respiratory bacterial infections associated with
cough, sputum production and impaired quality of life. Antibiotics are the main therapeutic option for managing bronchiectasis
exacerbations. Evidence suggests that inhaled antibiotics may be associated with more effective eradication of infective organisms and
a lower risk of developing antibiotic resistance when compared with orally administered antibiotics. However, it is currently unclear
whether antibiotics are more effective when administered orally or by inhalation.
Objectives
To determine the comparative efficacy and safety of oral versus inhaled antibiotics in the treatment of adults and children with
bronchiectasis.
Search methods
We identified studies through searches of the Cochrane Airways Group’s Specialised Register (CAGR), which is maintained by the
Information Specialist for the group. The Register contains trial reports identified through systematic searches of bibliographic databases
including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL, AMED, and PsycINFO,
and handsearching of respiratory journals and meeting abstracts. We also searched ClinicalTrials.gov and the WHO trials portal. We
searched all databases in March 2018 and imposed no restrictions on language of publication.
Selection criteria
We planned to include studies which compared oral antibiotics with inhaled antibiotics. We would have considered short-term use
(less than four weeks) for treating acute exacerbations separately from longer-term use as a prophylactic (4 weeks or more). We would
have considered both intraclass and interclass comparisons. We planned to exclude studies if the participants received continuous or
high-dose antibiotics immediately before the start of the trial, or if they have received a diagnosis of cystic fibrosis (CF), sarcoidosis,
active allergic bronchopulmonary aspergillosis or active non-tuberculous Mycobacterial infection.
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Data collection and analysis
Two review authors independently applied study inclusion criteria to the searches and we planned for two authors to independently
extract data, assess risk of bias and assess overall quality of the evidence using GRADE criteria. We also planned to obtain missing data
from the authors where possible and to report results with 95% confidence intervals (CIs).
Main results
We identified 313 unique records through database searches and a further 21 records from trial registers. We excluded 307 on the basis
of title and abstract alone and a further 27 after examining full-text reports. No studies were identified for inclusion in the review.
Authors’ conclusions
There is currently no evidence indicating whether orally administered antibiotics are more beneficial compared to inhaled antibiotics.
The recent ERS bronchiectasis guidelines provide a practical approach to the use of long-term antibiotics. New research is needed
comparing inhaled versus oral antibiotic therapies for bronchiectasis patients with a history of frequent exacerbations, to establish which
approach is the most effective in terms of exacerbation prevention, quality of life, treatment burden, and antibiotic resistance.
P L A I N L A N G U A G E S U M M A R Y
Oral versus inhaled antibiotics for people with bronchiectasis
Review question
We wished to know whether oral antibiotics (taken by mouth) or inhaled antibiotics are more effective for reducing the duration and
frequency of infective episodes of bronchiectasis, admissions to hospital and side effects, as well as reducing the risk of chest infections
not responding to treatment with antibiotics.
Background
Bronchiectasis is a long-term incurable condition where people get repeated bacterial chest infections that lead to frequent cough,
breathlessness and mucus production. These often occur three or more times a year and require treatment with antibiotics, either short-
term for the presenting chest infection, or long-term to prevent chest infections recurring. It was once thought to be an uncommon
disease but recent figures show that up to 5 people in every 1000 may have bronchiectasis and the death rate for people with the
condition may be more than twice that of the general population.
Antibiotics are commonly used to treat chest infections in people with bronchiectasis, to eliminate the specific types of bacteria that
cause the infection. Some antibiotics are more effective against particular types of bacteria compared to others, and these different
types of bacteria can develop resistance to treatment with antibiotics, making them less effective and reducing the subsequent choice
of antibiotic. Antibiotics can also be given to people in different ways, such as by mouth in pill form or breathed in as an inhalation.
We do not currently know which method of administering antibiotics, orally or by inhalation, is themost effective for treating recurrent
chest infections in terms of eliminating the bacteria, reducing the chances of people developing resistance to antibiotics and reducing
the symptoms of bronchiectasis.
We searched for all the published and unpublished available evidence, up until March 2018, which compared orally administered
antibiotics versus inhaled antibiotics.
Study characteristics
While there have been a few studies investigating the benefits of antibiotics for people with bronchiectasis, none have compared orally
administered antibiotics with inhaled antibiotics.
Quality of the evidence
There is no high-quality evidence available to determine whether oral or inhaled antibiotics are more helpful for people with bronchiec-
tasis. More research studies are needed to evaluate the effectiveness of oral antibiotics compared to inhaled antibiotics for reducing the
rate of chest infections and the chances of developing resistance to antibiotic therapy.
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B A C K G R O U N D
Description of the condition
Bronchiectasis is a chronic inflammatory lung disease that presents
with cough, sputum production and recurrent respiratory tract in-
fections (Pasteur 2010). It is defined radiologically by the presence
of permanently dilated airways usually visualised on computed to-
mography (CT). Bronchiectasis represents a final common path-
way of multiple disorders with the most common associations be-
ing with severe infections (pneumonia, childhood infection and
Mycobacterial infection), allergic bronchopulmonary aspergillosis,
rheumatological diseases, inflammatory bowel disease and disor-
ders of mucociliary clearance such as primary ciliary dyskinesia
(Lonni 2015). Treatments for bronchiectasis have historically been
extrapolated from cystic fibrosis with a focus on antibiotic treat-
ments and physiotherapy (Chalmers 2016).
Although previously considered a relatively rare disease (Kolbe
1996), bronchiectasis appears to be increasing, with higher rates in
developing countries, women and those aged over 60 years (Chang
2003; Weycker 2005; Habesoglu 2011; Seitz 2012). Prevalence
rates may also be higher in children from ethnic populations, for
example indigenous Australians (up to 14 per 1000) and Native
Alaskan children (up to 20.5 per 1000) (Singleton 2000; Chang
2002). International prevalence rates in the general population
are variable, ranging from 0.5 per 100,000 in Finland to 3.7 per
100,000 in New Zealand (European Lung White Book 2013).
More recent data from theUK reported an increase of over 60% in
prevalence over a nine-year period, with 263,000 adults livingwith
bronchiectasis in 2013 (Quint 2016). Incidence rates increased
by 63% to 35 per 100,000 in women and 27 per 100,000 in
men, with over 15,000 new cases in 2013. However, increased
prevalence may be partly attributable to increased awareness of
bronchiectasis and more efficient detection through CT scanning
(Goeminne 2016).
Mortality rates increased by 3% per year during a six-year period
to 2007 in England andWales (Roberts 2010). In the USA, hospi-
talisations also rose annually by 3% over a nine-year period (Seitz
2010). Average European mortality rates from 2005 to 2009 are
estimated at 0.3 per 100,000 general population in EU countries
(from 0.01 in Germany to 1.18 in the UK) and 0.2 per 100,000
in nine non-EU countries (from 0.01 in Azerbaijan to 0.67 in
Kyrgyzstan) (European Lung White Book 2013). Recent age-ad-
justed mortality rates for the UK were more than twice that of
the general population (2.26 times higher in women; 2.14 times
higher in men) (Quint 2016).
Description of the intervention
Bronchiectasis is characterised by a common pathophysiological
pathway that consists of a vicious cycle. Three elements play a
pivotal role in this cycle: inflammation, infection and airway dam-
age by enzymatic components. In this cycle, infection or colonisa-
tion by various micro-organisms cause an inflammatory response.
When this inflammation is not able to clear the micro-organism,
the inflammation can become chronic and even excessive com-
pared to the bacterial burden. This can then finally result in airway
damage and remodelling (Goeminne 2010).
Interventions aiming to reduce or break this vicious cycle often
focus on the treatment of the chronic bacterial infection. Data
show that these chronic infections are most often caused by Gram-
negatives, with a special focus on Pseudomonas aeruginosa as this
has been linked with more severe disease and increased morbidity
and mortality (Wilson 2016). To treat or eradicate these chronic
infections, long courses and high dosage of systemic antibiotic
treatment are often required. This is frequently accompanied by
side effects and can also result in resistance. Therefore, inhaled
antibiotics are increasingly being considered, as they can deliver
high concentrations of the antibiotic at the site of infection with
less systemic absorption and toxicity, but can result in increased
airway irritation or bronchospasm (Geller 2009).
How the intervention might work
A recent Cochrane review of 18 trials in patients with bronchiec-
tasis receiving prolonged antibiotics, showed that there was a sig-
nificant reduction of exacerbation risk (Hnin 2015). Further-
more, recent data clearly suggest an important relationship be-
tween inflammation and bacterial load/presence in bronchiecta-
sis. Chronic Pseudomonas aeruginosa infection was associated with
increased matrix metalloprotease activity and a higher bacterial
load was associated with an increase in hospitalisations, exacer-
bations and symptom severity (Chalmers JD 2012; Goeminne
2014). Chalmers et al also showed that both short- and long-term
antibiotic treatment significantly reduced airway and systemic in-
flammation. This is in line with a series of long-term systemic an-
tibiotic therapy trials with macrolides, proving that long-term oral
macrolides are useful for patients with bronchiectasis in reduc-
ing exacerbations and improving clinical symptoms (Wong 2012;
Altenburg 2013; Serisier 2013). It is speculated that macrolides
not only act through their antibacterial activity but also have anti-
inflammatory and immunomodulatory effect (Altenburg 2011a).
These long-term oral macrolide treatments, however, raise some
concerns as to safety and bacterial resistance (Altenburg 2011b).
Inhaled antibiotics may provide an effective suppressive antibiotic
therapy with an acceptable safety profile in adult patients with sta-
ble bronchiectasis and chronic bronchial infection. Their use has
been widespread in CF since the early 1990s, as inhaled antibiotics
improve lung function and reduce exacerbation rates (Ryan 2011).
For inhaled antibiotics, different antibiotic regimens have been in-
vestigated in non-CF bronchiectasis, including inhaled amikacin,
aztreonam, ciprofloxacin, gentamicin, colistin and tobramycin.
The antibiotics chosen often have a concentration-dependent ef-
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fect, where a greater area under the curve/minimum inhibitory
concentration ratio improves bacterial killing (Restrepo 2015). As
resistance is one of the concerns in chronic antibiotic treatment,
these inhaled antibiotics may achieve very high concentrations of
the drug in the airways, overcoming bacterial resistance (Dudley
2008; Rubin 2008; Quon 2014). On the other hand, inhalation
antibiotic treatment is hampered by a delivery that is not uniform,
creating a concentration gradient with lower concentrations in
deeper parts of the lung (Rubin 2008). In non-CF bronchiectasis,
a recent review found that long-term inhaled antibiotics can effec-
tively reduce the sputum bacterial density, increase Pseudomonas
aeruginosa eradication and attenuate the risk of exacerbation, but
with higher risk of wheeze and bronchospasm (Yang 2016).
Why it is important to do this review
In meta-analyses of trials involving participants with non-CF
bronchiectasis, authors have concluded that inhaled antibiotics re-
duced sputum bacterial load and the risk of acute exacerbation,
with an acceptable safety profile, when compared to symptomatic
treatment or placebo (Brodt 2014; Yang 2016). However, in real-
ity, clinicians will often be faced with the choice between various
routes of delivering antibiotics, not only the choice of whether or
not to give them. A comparison between the oral and inhaled route
was highlighted as a priority in a recently published overview of
interventions for bronchiectasis (Welsh 2015).The potential bene-
fits of improved bacterial killing and reduced risk of bacterial resis-
tance described above need to be weighed against the cost of drug
delivery via inhalation and specific side effects associated with this
route, such as bronchospasm and wheeze (BNF (online); Brodt
2014; Yang 2016).
Therefore in this review we will include studies that directly com-
pare the effectiveness and safety of delivering antibiotics by in-
halation or orally, both in an acute setting and for longer-term
prophylaxis in people with bronchiectasis. We intend to sum-
marise the evidence to provide the most up-to-date information
for guideline developers, clinicians and patients, and highlight fu-
ture research needs. This review is being conducted alongside four
other closely related Cochrane reviews on macrolide antibiotics
for bronchiectasis (Kelly 2016); dual antibiotics for bronchiectasis
(Felix 2017); head-to-head trials of antibiotics for bronchiectasis
(Kaehne 2017); and continuous versus intermittent antibiotics for
bronchiectasis (Donovan 2017).
O B J E C T I V E S
To determine the comparative efficacy and safety of oral versus
inhaled antibiotics in the treatment of adults and children with
bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomised controlled trials (RCTs), re-
ported as full-text or published as abstract only or unpublished
data.
Types of participants
We planned to include adults and children diagnosed with
bronchiectasis by bronchography, plain film chest radiograph, or
high-resolution computed tomography. We planned to exclude
studies if the participants received continuous or high-dose an-
tibiotics immediately before the start of the trial, or if they had
received a diagnosis of cystic fibrosis (CF), sarcoidosis, active al-
lergic bronchopulmonary aspergillosis or active non-tuberculous
Mycobacterial infection.
Types of interventions
We planned to include studies comparing oral antibiotics with
inhaled antibiotics. We would have considered short-termuse (less
than 4 weeks) for treating acute exacerbations separately from
longer-term use as a prophylactic (4 weeks or more). We would
have considered both intraclass and interclass comparisons. We
planned to include the following comparison groups.
1. Inhaled aminoglycosides versus oral antibiotics
2. Inhaled polymyxin versus oral antibiotics
3. Inhaled beta-lactam versus oral antibiotics
Types of outcome measures
Primary outcomes
We planned to include the following primary outcomes for short-
term therapy, longer-term therapy or both, as indicated.
1. Duration of exacerbation (short-term)
2. Exacerbation (both), e.g. frequency during follow-up or
time to first exacerbation
3. Hospitalisations due to exacerbations (both)
4. Serious adverse events (both)
Secondary outcomes
1. Response rates as defined by study authors, e.g. diary cards
of physician global assessment
2. Sputum volume and purulence
3. Measures of lung function, e.g. forced expiratory volume in
one second (FEV1)
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4. Adverse events, e.g. cardiac arrhythmias, gastrointestinal
symptoms, hearing impairment, bronchospasm
5. Mortality
6. Emergence of resistance to antibiotics or treatment
emergent pathogens
7. Exercise capacity, e.g. Six-Minute Walk Test (6MWT)
8. Quality of life (QOL), e.g. St George Respiratory
Questionnaire (SGRQ) or alternative QOL tools
9. Eradication of pathogens
Reporting one or more of the outcomes listed here in the study
was not used as an inclusion criterion for the review.
We planned to include the above secondary outcomes for both
short-term and long-term therapy.
Search methods for identification of studies
Electronic searches
We identified studies from the Cochrane Airways Specialised Reg-
ister, which is maintained by the Information Specialist for the
group. The Cochrane Airways Specialised Register contains stud-
ies identified from several sources:
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org);
2. Weekly searches of MEDLINE Ovid SP, 1946 to date;
3. Weekly searches of Embase Ovid SP, 1974 to date;
4. Monthly searches of PsycINFO Ovid SP, 1967 to date;
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature), 1937 to date;
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine);
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the SpecialisedRegister are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference
proceedings are in Appendix 1. See Appendix 2 for search terms
used to identify studies for this review.
We also conducted a search of US National Institutes of Health
OngoingTrialsRegisterClinicalTrials.gov (www.clinicaltrials.gov)
and the World Health Organization International Clinical Tri-
als Registry Platform (apps.who.int/trialsearch/). We searched all
databases from their inception to 5 March 2018, and we imposed
no restriction on language of publication.
Searching other resources
We planned to check the reference lists of all primary studies and
review articles for additional references. As there are multipleman-
ufacturers of both oral and inhaled antibiotics and many are off-
patent, we did not conduct a search of manufacturers’ websites for
study information.
Weplanned to search for errata or retractions from included studies
published in full text on PubMed and report the date of this search
within the review.
Data collection and analysis
Selection of studies
Two review authors (TD and RN) screened the titles and abstracts
of the search results independently and coded them as ’retrieve’ (el-
igible or potentially eligible/unclear) or ’do not retrieve’. We then
retrieved the full-text study reports of all potentially eligible stud-
ies and two review authors (TD and RN) independently screened
them for inclusion, recording the reasons for exclusion of ineli-
gible studies. We did not have any disagreements, but if we had
then we planned to resolve this through discussion or, if required,
by consulting a third person/review author (SS/SJM).We planned
to identify and exclude duplicates and collate multiple reports of
the same study so that each study, rather than each report, would
be the unit of interest in the review. We recorded the selection
process in sufficient detail to complete a PRISMA flow diagram
and ’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We planned to use a data collection form for study characteristics
and outcome data, which was used for a similar review on a closely
related topic. For future updates, we will extract the following
study characteristics from included studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: baseline exacerbation data (e.g. frequency,
duration), primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest
of trial authors.
If we identify eligible trials in future updates of this review, two
review authors (RN and TD) will independently extract outcome
data from included studies. We will note in the ’Characteristics
of included studies’ table if outcome data were not reported in a
usable way. We will resolve disagreements by consensus or by in-
volving a third person/review author (SS/SJM).One review author
will transfer data into the Review Manager file (RevMan 2014).
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This entered data will be double-checked for accuracy by another
review author by comparing the data presented in the systematic
review with the study reports.
Assessment of risk of bias in included studies
In future updates, if any studies meet the inclusion criteria, then
two review authors will assess risk of bias independently for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will resolve
any disagreements by discussion or by involving another author
(SS/SJM).We will assess the risk of bias according to the following
domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.
If we identify eligible trials in future updates of this review, we
will judge each potential source of bias as high, low or unclear
risk, and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies for
each of the domains listed.We plan to consider blinding separately
for different key outcomes where necessary (e.g. for unblinded
outcome assessment, risk of bias for all-cause mortality may be
very different than for a patient-reported quality of life scale).
Where information on risk of bias relates to unpublished data or
correspondence with a trialist, we will note this in the ’Risk of bias’
table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol
and planned to justify any deviations from it in the ’Differences
between protocol and review’ section of the systematic review.
Measures of treatment effect
If we identify eligible trials in future updates of this review, we will
adhere to the following data analysis plan.
We will analyse dichotomous data as odds ratios (ORs) and con-
tinuous data as mean differences (MDs) or standardised mean
differences (SMDs). We will enter data presented as a scale (e.g.
quality of life measures) with a consistent direction of effect. We
will describe skewed data narratively (for example, as medians and
interquartile ranges for each group).
We will undertake meta-analyses only where this is meaningful;
that is, if the treatments, participants and the underlying clinical
question are similar enough for pooling to make sense.
Where multiple trial arms are reported in a single study, we will
include only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) are combined in the
samemeta-analysis, wewill either combine the active arms or halve
the control group to avoid double-counting.
If adjusted analyses are available (ANOVA or ANCOVA) we will
use these as a preference in our meta-analyses. If both change from
baseline and endpoint scores are available for continuous data, we
will use change from baseline scores unless there is low correlation
between measurements in individuals. If a study reports outcomes
at multiple time points (repeated observations), we will perform
separate analyse for different periods of follow-up.
We will use intention-to-treat (ITT) analyses where they are re-
ported (i.e. all those who were randomised are analysed) instead
of completer or per protocol analyses.
Unit of analysis issues
If we identify eligible trials in future updates of this review, we
will adhere to the following plan. For dichotomous outcomes, we
will use participants, rather than events, as the unit of analysis
(i.e. number of children admitted to hospital, rather than number
of admissions per child). However, if rate ratios are reported in a
study, wewill analyse themon this basis.Wewill onlymeta-analyse
data from cluster-RCTs if the available data have been adjusted
(or can be adjusted), to account for the clustering.
Dealing with missing data
If we identify eligible trials in future updates of this review, we
will contact investigators or study sponsors in order to verify key
study characteristics and obtain missing numerical outcome data
where possible (e.g. when a study is identified as an abstract only).
Where this is not possible, and the missing data are thought to
introduce serious bias, we will take this into consideration in the
GRADE rating for affected outcomes.
Assessment of heterogeneity
If we identify eligible trials in future updates of this review, we
will use the I² statistic to measure heterogeneity among the studies
in each analysis. If we identify substantial heterogeneity we will
report it and explore the possible causes by prespecified subgroup
analysis.
Assessment of reporting biases
If we identify eligible trials in future updates of this review, and are
able to pool more than 10 studies, we will create and examine a
funnel plot to explore possible small study and publication biases.
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Data synthesis
If we identify eligible trials in future updates of this review, we
will use a random-effects model and perform a sensitivity analysis
with a fixed-effect model.
’Summary of findings’ table
If we identify eligible trials in future updates of this review, we
will create a ’Summary of findings’ table using the following out-
comes: duration of exacerbations, exacerbations (frequency and
time to first exacerbation), frequency of hospitalisations due to
exacerbations, serious adverse events, response rates, mortality and
quality of life.We will use the five GRADE considerations (risk of
bias, consistency of effect, imprecision, indirectness and publica-
tion bias) to assess the quality of a body of evidence as it relates to
the studies that contribute data for the prespecified outcomes. We
will use the methods and recommendations described in Section
8.5 and Chapter 12 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011), using GRADEpro software
(GRADEpro GDT). We will justify all decisions to downgrade
the quality of studies using footnotes and we will make comments
to aid the reader’s understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
If we identify eligible trials in future updates of this review, we
plan to carry out the following subgroup analyses.
1. Adults versus children (18 years or younger)
2. Patients chronically infected with Pseudomonas aeruginosa
versus those not infected with Pseudomonas aeruginosa
3. Macrolide versus non-macrolide oral antibiotic
We will use the following outcomes in subgroup analyses.
1. Exacerbation duration (short-term therapy)
2. Exacerbation, e.g. frequency during follow-up or time to
first exacerbation
3. Hospitalisation due to exacerbations
4. Adverse events
We will use the formal test for subgroup interactions in Review
Manager (RevMan 2014).
Sensitivity analysis
If we identify eligible trials in future updates of this review, we plan
to carry out the following sensitivity analyses, removing the studies
judged as high risk of bias from the primary outcome analyses.
1. Exacerbation duration (short-term therapy)
2. Exacerbation, e.g. frequency during follow-up or time to
first exacerbation (both)
3. Hospitalisation due to exacerbations
4. Adverse events
We will compare the results from a fixed-effect model with the
random-effects model.
R E S U L T S
Description of studies
Results of the search
We identified 313 unique records through database searches and a
further 21 records from trial registries (www.ClinicalTrials.gov and
www.who.int/ictrp/en/). We excluded 307 records on the basis of
title and abstract and a further 27 after examining the full text.
Details of the search are shown in the flow diagram Figure 1. The
searches were conducted in March 2018.
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Figure 1. Study flow diagram
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Included studies
Wedid not identify any randomised controlled trials (RCTs)meet-
ing our prespecified inclusion criteria.
Excluded studies
We excluded 27 studies after reviewing the full-text publication.
Reasons for exclusion were: trial compared an inhaled or nebulised
antibiotic to placebo or usual care (n = 20); the record was a letter
to editor (n = 2); trial compared addition of inhaled antibiotics
to oral antibiotics (n = 2); trial compared intravenous followed by
oral antibiotics for an acute exacerbation of bronchiectasis to a full
intravenous course of antibiotics (n = 1); trial was not randomised
and investigated impact of long- and short-term antibiotic treat-
ment on inflammation (n = 1); and trial compared addition of
inhaled antibiotics to intravenous antibiotics versus intravenous
antibiotics alone (n = 1). See Characteristics of excluded studies.
Risk of bias in included studies
We did not identify any RCTs meeting our prespecified inclusion
criteria.
Effects of interventions
We did not identify any RCTs meeting our prespecified inclusion
criteria.
D I S C U S S I O N
Summary of main results
It was not possible to achieve our aim to provide an overview of
the effectiveness of oral versus inhaled antibiotics for bronchiec-
tasis with respect to our predefined outcomes; our comprehensive
search found no randomised controlled trials meeting our prede-
fined inclusion criteria (see: Criteria for considering studies for
this review). The absence of evidence addressing this question is a
cause for considerable concern as uncertainties remain regarding
the most effective route of administration for reducing exacerba-
tions and minimising the development of antibiotic resistance .
Overall completeness and applicability of
evidence
Unfortunately we were unable to assess the completeness and
applicability of evidence on oral versus inhaled antibiotics for
bronchiectasis as no studies met our inclusion criteria.
Quality of the evidence
Wewere unable to consider the quality of evidence comparing oral
versus inhaled antibiotics for bronchiectasis as no relevant clinical
trials were available.
Potential biases in the review process
Our searches for relevant clinical trials were extensive and compre-
hensive, with expert support from the Cochrane Airways Group.
Agreements and disagreements with other
studies or reviews
We did not identify any systematic reviews or clinical trials rele-
vant to the comparison between oral versus inhaled antibiotics for
bronchiectasis.
European Respiratory Society guidelines for the management of
bronchiectasis suggest use of an inhaled antibiotic over oral an-
tibiotics for adults with bronchiectasis and chronic P. aeruginosa
infection, unless inhaled antibiotics are contraindicated, not tol-
erated or ineffective (Polverino 2017). Macrolides (azithromycin,
erythromycin) are recommended in preference to inhaled antibi-
otics for adults with bronchiectasis and no infection with P. aerug-
inosa. When macrolides are contraindicated, not tolerated or inef-
fective, other oral antibiotics are recommended (Polverino 2017).
A Cochrane review on cystic fibrosis reported a reduction in pul-
monary exacerbations and a small improvement in lung func-
tion over six months with macrolide antibiotics (Southern 2012).
However, there are no randomised controlled trials of oral versus
inhaled antibiotic treatments to prevent exacerbations in cystic fi-
brosis, and clinical guideline recommendations are inconsistent.
The USACystic Fibrosis Foundation guidelines recommend both
oral azithromycin and inhaled tobramycin in patients with cys-
tic fibrosis bronchiectasis chronically infected with P. aeruginosa
(Flume 2007). In contrast, UK guidelines on cystic fibrosis rec-
ommend nebulised antipseudomonal antibiotics for patients with
chronic P. aeruginosa infection, and azithromycin as an additional
therapy for deteriorating patients (Cystic Fibrosis Trust 2009). In
both cystic fibrosis and bronchiectasis guidelines, most of the ev-
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idence for treating patients with P. aeruginosa infection is from
studies of inhaled antimicrobials and so these are often used first.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no evidence from randomised controlled trials
to indicate whether orally administered antibiotics are more or less
beneficial than inhaled antibiotics. Until such evidence is available,
practitioners may consider consulting local, national and interna-
tional guidelines, such as the European Respiratory Society guide-
lines for the management of bronchiectasis (Polverino 2017).
Implications for research
The above recommendations from the European Respiratory So-
ciety guidelines are not based on direct evidence as there are no
studies that compare inhaled versus oral antibiotics, either in pa-
tients with P. aeruginosa infection or in other populations of pa-
tients (Polverino 2017). The recommendations are based largely
on the experience of inhaled antibiotics in cystic fibrosis, and are
influenced by the fact that most trials to date have used inhaled
antibiotics for patients with P. aeruginosa infection and oral antibi-
otics in populations without P. aeruginosa (Chalmers 2015). The
primary objective of both oral and inhaled antibiotic therapy in
bronchiectasis is the prevention of exacerbations (Hill 2017).
It would therefore be desirable to see randomised controlled tri-
als comparing the administration of inhaled versus oral antibi-
otic therapies for bronchiectasis patients with a history of fre-
quent exacerbations, with the aim of establishing which approach
is most effective in terms of exacerbation prevention, quality of
life, treatment burden, and antibiotic resistance (Aliberti 2016b).
Since bronchiectasis is a clinically heterogeneous disease with four
potential disease clusters (pseudomonas infection, other chronic
infection, daily sputum, dry bronchiectasis), it is likely that differ-
ent patient populations will response differently to inhaled or oral
antibiotic treatments, and so it is a research priority to identify
clinical phenotypes of subgroups likely to respond to each therapy
(Aliberti 2016a).
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NCT00749866 2008 Wrong comparator. The trial compares inhaled gentamicin to placebo
NCT01313624 2011 Wrong comparator. The trial compares inhaled aztreonam to placebo
NCT01677403 2012 Wrong comparator. The trial compares inhaled tobramycin to placebo
O’Donnell 1999 Wrong comparator. The trial compares inhaled tobramycin to placebo
O’Donnell 2016 Wrong comparator. The trial compares inhaled ciprofloxacin to placebo
Orriols 1999 Wrong comparator. The trial compares inhaled ceftazidime and tobramycin to usual care
Santiveri 1995 Wrong comparator. The trial compares addition of inhaled antibiotics to intravenous antibiotics versus
intravenous antibiotics alone
Serisier 2012 Letter to editor regarding trial of inhaled gentamicin compares to placebo
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Shrewsbury 2004 Wrong intervention. The trial compares the addition of inhaled tobramycin to ciprofloxacin to ciprofloxacin
alone
Soyza 2015 Wrong comparator. The trial compares inhaled ciprofloxacin to placebo
Tabernero 2012 Wrong comparator. The trial compares inhaled colistin to usual care
Terpstra 2016 Wrong comparator. The trial compares two different doses of inhaled tobramycin to placebo
Twiss 2008 Wrong comparator. The trial compares inhaled gentamicin to placebo
Twiss 2009 Wrong comparator. The trial compares inhaled gentamicin to placebo
Wilson 2011 Wrong comparator. The trial compares inhaled ciprofloxacin to placebo
Wong 2004 Wrong intervention and wrong comparator. Trial compares intravenous followed by oral antibiotics for an
acute exacerbation of bronchiectasis, versus a full intravenous course of antibiotics
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D A T A A N D A N A L Y S E S
This review has no analyses.
C O N T R I B U T I O N S O F A U T H O R S
PG and LF independently screened the search in consultation with SS, SJM and JDC. LF, SS and SJM completed the analyses and
Results section. All review authors contributed to the Discussion, Conclusions and remaining sections of the review.
D E C L A R A T I O N S O F I N T E R E S T
SS: is the lead applicant on a grant from Edge Hill University that provides support staff for a number of bronchiectasis reviews. She is
also an editor with the Cochrane Airways Group.
LF: none known
SM: none known
RN: is Joint Co-ordinating Editor with the Cochrane Airways Group.
PCG: has received lecture fees from Novartis, Chiesi, Eurogenerics, Astra Zeneca and Boehringer and received travel accommodation
from Chiesi and Novartis.
JDC: has received research funding from Astrazeneca and Pfizer, and has received lecture fees or served on advisory boards for Bayer,
Griffols, Astrazeneca, Pfizer, Napp and Chiesi.
S O U R C E S O F S U P P O R T
Internal sources
• Edge Hill University, UK.
Provided funding for a part-time review author (LF) to support a series of Cochrane Reviews on bronchiectasis.
External sources
• All authors, UK.
This review was completed, in part, through a grant of £5,000 from the Cochrane Review Support Programme.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As there are multiple manufacturers of both oral and inhaled antibiotics and many are off-patent, we did not conduct a search of
manufacturers websites.
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